Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments (DETECSEPS)

11 novembre 2026 aggiornato da: Assistance Publique - Hôpitaux de Paris

Real-life Evaluation of the Impact of Early Detection of Sepsis With the NEWS2 Clinical Alert Score Combined to Circulating Concentrations of the H3.1 Nucleosome, on the Care Pathway of Adults Presenting to the Emergency Department With a Proven or Strongly Suspected Infection

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.

In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.

In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.

The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.

IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.

Tipo di studio

Interventistico

Iscrizione (Stimato)

1000

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Boulogne-Billancourt, Francia
        • Hôpital Ambroise Paré - AP-HP
        • Contatto:
      • Lyon, Francia
        • Hôpital de la Croix Rousse - HCL
        • Contatto:
      • Lyon, Francia
      • Lyon, Francia
      • Paris, Francia
        • Hôpital Bichat - AP-HP
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria

  1. All genders patients

  2. Aged of 18 years or older

  3. Proven or suspected infection

  4. At least one risk factor for sepsis (cf HAS recommendations) :

    • Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery

    • Inborn immune deficit

    • Acquired immune deficit :

      • Diseases related : Cancer, Transplant patient, Chronic inflammatory or autoimmune disease, HIV, Asplenic anatomical or functional (Sickle cell disease)
      • Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, Immunosuppressive drugs,
    • Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis

  5. Informed consent

Exclusion Criteria:

  1. Refused to consent participating in the study,
  2. Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  3. Previous enrolment
  4. Pregnancy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Diagnostico
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: NEWS2 and H3.1-guided diagnostic and management strategy

Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol.

Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below :

  • If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation.
  • If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required.
  • In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

Altro: Usual care

Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system.

The result will not be disclosed to the investigators and healthcare staff in the control arm

The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system:

  1. respiration rate
  2. oxygen saturation
  3. systolic blood pressure
  4. pulse rate
  5. level of consciousness or new confusion
  6. temperature

The result will not be disclosed to the investigators and healthcare staff in the control arm

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients with optimized care pathway
Lasso di tempo: 24 hours after inclusion

The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission

If sepsis is confirmed:

  • Implementation of good clinical practice recommendations within 3 hours of arrival at ED (3-hour bundle of the Surviving Sepsis Campaign & HAS recommendations)
  • ICU admission within 6 hours of arrival at ED
24 hours after inclusion

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Death rate
Lasso di tempo: At 6 months
At 6 months
Cumulative incidence of direct ICU admission
Lasso di tempo: Up to 6 months
Up to 6 months
Cumulative incidence of secondary ICU admission
Lasso di tempo: Up to 6 months

ie after admission to ward

Up to 6 months
Proportion of patients with cognitive, psychological, or physical sequelae
Lasso di tempo: Up to 6 months
Up to 6 months
Proportion of patients requiring renal, respiratory, or cardiovascular support
Lasso di tempo: Up to day 7

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 7
Proportion of patients requiring renal, respiratory, or cardiovascular support
Lasso di tempo: Up to day 28

Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

Up to day 28
Time to discharge to home
Lasso di tempo: Up to 6 months
Up to 6 months
Time to resume previous social and professional activities
Lasso di tempo: Up to 6 months
Up to 6 months
Quality of life - EQ-5D-5L
Lasso di tempo: At 6 months

The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status

At 6 months
Quality of life - SF36
Lasso di tempo: At 6 months

The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning.

At 6 months
Cost of strategies and care pathways
Lasso di tempo: At 6 months

Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months.

At 6 months
Proportion of cases for which the combined diagnostic protocol is applied as intended
Lasso di tempo: Up to 6 months

e.g., correct use of NEWS2 and H3.1 nucleosome testing

Up to 6 months
Proportion of test results available below a meaningful clinical duration to allow for patient management.
Lasso di tempo: Up to 6 months
Up to 6 months
Proportion of appropriate integration of tests results within clinical workflow
Lasso di tempo: Up to 6 months
Up to 6 months
Proportion of avoided hospitalization among patients receiving the intervention
Lasso di tempo: Up to 6 months
Up to 6 months
Evolution of the proportion of eligible patients included over time
Lasso di tempo: Up to 6 months
Up to 6 months
Environmental impact of study-related procedures
Lasso di tempo: Up to 6 months

The environmental footprint of each component of the research process will be assess, including:

  • Biological sampling: Biomarkers will be measured from routine care tubes, avoiding the use of dedicated research tubes, which often expire unused and contribute to waste.
  • Patient transport: No additional on-site visits will be required for the study, limiting travel-related emissions (Lyle et al., BMJ, 2009).
  • Study documentation: Digital consent forms (e-consent) will be preferred. When choosing between paper or electronic formats, the environmental impact of printing, document replacement after amendments, and digital storage will be considered.

All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study.

Up to 6 months
Life cycle analyse (LCA)
Lasso di tempo: Up to 6 months

Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools.

Up to 6 months
LCA comparison of the two clinical strategies
Lasso di tempo: Up to 6 months

The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes.

The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study.

Up to 6 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines
Lasso di tempo: At baseline, day 1 and day 7
At baseline, day 1 and day 7
Multi-omic profile
Lasso di tempo: At baseline

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At baseline
Multi-omic profile
Lasso di tempo: At day 1

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 1
Multi-omic profile
Lasso di tempo: At day 7

Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

At day 7
Innate immune cells activation markers and sub-populations
Lasso di tempo: At baseline

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At baseline
Innate immune cells activation markers and sub-populations
Lasso di tempo: At day 1

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 1
Innate immune cells activation markers and sub-populations
Lasso di tempo: At day 7

Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

At day 7

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Cattedra di studio: Djillali Annane, MD PhD, IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

2 dicembre 2027

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

30 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • APHP260617

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP

Periodo di condivisione IPD

Within 6 months from publication of the study results

Criteri di accesso alla condivisione IPD

Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi